The broader pattern of GLP-1 drugs reducing addictive and compulsive behavior has shown up across multiple datasets, including a 606,000-veteran cohort published in BMJ earlier this year showing meaningful reductions in alcohol, nicotine, and opioid use disorder rates in GLP-1 users
IV pushes usually contain fewer ingredients (13) in lower volumes and are often used when time is limited or a specific nutrient is being targeted
Some patients experience mild bloating indefinitely, but dietary adjustments and slower eating usually keep it manageable
Confusing these two dosing systems can lead to serious medication errors
NAD+-replacement treatment may help cure addiction while promoting mitochondrial health and homeostasis, genomic stability, neuroprotection, healthy aging, and lifespan